<DOC>
	<DOC>NCT00166504</DOC>
	<brief_summary>This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea. The primary hypothesis being tested is that daily administration of Vytorin will result in a greater reduction of low density lipoprotein cholesterol (LDL-C) concentration from baseline after 6 weeks treatment compared to atorvastatin.</brief_summary>
	<brief_title>Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<criteria>Clinical diagnosis of hypercholesterolemia LDLC &gt;/= 130 mg/dL but &lt;/=250 mg/dL and triglyceride (TG) &lt;/= 350 mg/dL National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guideline Hypersensitivity to 3hydroxy3methylglutarylCoA reductase (HMGCoA reductase) inhibitors or Ezetimibe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>